 ContraFect Corporation CFRX, a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents DLAs, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced financial results for the first quarter ended March 31, 2020. We began 2020 in stride, enrolling patients into our Phase 3 DISRUPT superiority study of exebacase and then receiving Breakthrough Therapy designation from the FDA for exebacase for the treatment of MRSA bloodstream infections, said Roger J. Pomerantz, M.D., President, Chief Executive Officer, and Chairman of ContraFect. In February, the Company announced that that the U.S. Food and Drug Administration FDA granted Breakthrough Therapy designation to exebacase for the treatment of methicillin-resistant Staphylococcus aureus MRSA bloodstream infections bacteremia, including right-sided endocarditis, when used in addition to standard-of-care SOC anti-staphylococcal antibiotics in adult patients. 